The global skeletal dysplasia market is anticipated to expand at a moderate CAGR during forecast period, between 2021 and 2028. The growth of the market is attributed to rising prevalence of skeletal dysplasia across the globe.
Skeletal dysplasia is a rare disease that is caused by a defect in a particular gene, known as a genetic mutation. Skeletal dysplasia is a group of diseases that constitute over 450 conditions in the skeleton. This disease affects the development and growth of the bone and cartilage. Skeletal dysplasia may lead to abnormalities related to bone size, density, shape, and short stature.
Symptoms of skeletal dysplasia include missing limbs, stubby fingers, missing ribs, fractured bones, joint pain, scoliosis, club feet, developmental delays, cognitive impairments, and duplication of fingers or toes. The common types of skeletal dysplasia include thanatophoric dysplasia, hypochondroplasia, campomelic dysplasia, osteogenesis imperfect, and achondrogenesis. The treatment of skeletal dysplasia mainly includes prescription of the growth hormones and surgical procedures.
The report on skeletal dysplasia market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.
2018 & 2019
Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
Market Scope, Analysis, Share, Competitive Analysis, Growth Facts, Restraints, Opportunities and Revenue Forecast
Strong presence of pipeline products drives segment growth
On the basis of types, the global skeletal dysplasia market can be categorized as x-linked hypophosphatemia, hypophosphatasia, achondroplasia, fibrodysplasia ossificans progressive, multiple osteochondromas, and others. The fibrodysplasia ossificans progressive segment held a substantial market share and is expected to register significant CAGR during the forecast period. The segmental growth is attributed to the rising awareness of the disease and high number of pipeline products for the treatment of fibrodysplasia ossificans progressive disorder.
Several benefits of surgery over other treatments is fueling the segmental growth
By treatments, the market can be segregated into medications, surgery, and others. The surgery segment is anticipated to expand at a considerable CAGR owing to the benefits such as faster outcomes and effectiveness of surgery over other treatments. Most of the patients prefer surgery, especially for achondroplasia and hypophosphatasia. Rising incidence of these disease types are expected to contribute to the segment growth during the forecast period.
Access to a large patient pool in hospitals is propelling the segmental growth
Based on end-users, the market can be divided into hospitals, ambulatory surgical centers, and others. The hospitals segment held a significant market share and is expected to expand at a moderate CAGR during the forecast period. Increase in the number of patients visiting hospitals owing to the advantages such as availability of advanced equipment for diagnosis and access to a large patient pool is driving the growth of the segment.
North America constituted a significant share of the market
In terms of regions, the global skeletal dysplasia market can be segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to expand at a considerable CAGR during the forecast period. The growth is attributed to the factors such as surging research & development initiatives for the treatment of skeletal dysplasia and growing occurrence of the diseases in the region. For instance, as per the recent article published by the American Dental Association, in 2018, X-linked Hypophosphatemia affects around 3,000 children and 12,000 adults in the U.S.
Key players in the skeletal dysplasia market include Dr. Reddy’s Laboratories Ltd., Regeneron, BioMarin, Clementia, Ultragenyx Pharmaceutical, Novartis AG, Eli Lilly and Company, Alexion, Cipla Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, CELGENE CORPORATION, and Teva Pharmaceutical Industries Ltd.
Collaborations, mergers, acquisitions, agreements, and partnerships are some growth strategies adopted by these players to strengthen their geographical presence.
Some other reports from this category!